Shares of Novocure (NASDAQ: NVCR) jumped Wednesday after the company reported before the open that its phase 3 METIS clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Hot List

Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary EndpointMarch 27, 2024 9:29 AM Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain MeMarch 27, 2024 9:29 AM Midday movers: GameStop falls; Merck, Robinhood and Moderna riseMarch 27, 2024 8:17 AM Novocure's device shown to slow cancer progression in the brain in trialMarch 27, 2024 7:12 AM Form 8-K NovoCure Ltd For: Mar 27March 27, 2024 7:00 AM Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary EndpointMarch 27, 2024 7:00 AM METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CMarch 27, 2024 7:00 AM